havana atm
TRANSCRIPT
Havana, Global Forum for Health Research
Wim Leereveld19 november 2009
2 .000.000.000 people
Together with all stakeholders we aim to define the role of the Industry
4
What is the Pharmaceutical
Industry currently doing?
Who are they?
What should they be doing ?
Good guys or
bad guys? Who knows
the answers?
The role of the Pharmaceutical
Industry
The principle of the Index is based on Measurement, Transparency and Benchmarking
Measurement: “What gets measured get’s managed”• The criteria on which the companies are rated will have an
impact on the Pharmaceutical Industry’s role and priorities within access to medicine
Transparency• Recognize and reward Pharmaceutical Companies for good
behaviour• Analyze and learn from and show best practices
Benchmark• Comparing peers to peers, adheres to the competitive nature
of the pharmaceutical industry 5
Management20%
Influence
10%
R&D20%Patenting
10%
Capacity15%
Pricing15%
Drug Donatio
ns6%
Philanthropy4%
The Index 2008 methodology consisted of 8 criteria each covering many indicators
E.g.: policy and level of disclosure and monitoring
E.g.: active advocacy towards better access to medicine
E.g.: partnerships and investment in R&D into treatments for neglected diseases
E.g.: voluntary licensing agreements and respect for TRIPS agreements
E.g.: technology transfer agreements with local companies
E.g.: Pricing mechanism policies and their scope, pricing levels, pricing reviews
E.g.: compliance with WHO’s Guidelines for Drug Donations
Other philanthropic programmes e.g.: # of hospitals built or supported
Note: This weighting was applied to Originator Companies, Generic Companies had a different weighting 6
7
Highest scoring company in Index 2008: GlaxoSmithKline PLC
Lowest scoring company in Index 2008: Schering-Plough Corp.
So who are all these stakeholders that are involved in defining what Pharmaceutical companies’ role should be
8
Experts
Patients / Healthcare
Practitioners
Pharmaceutical Industry
Academia Multilateral Organizations
Investors NGO’s
GovernmentAccess to Medicine Index
Executive Review Commission guided by Stakeholder Roundtables
Stakeholder Engagement Process
• An online survey• Stakeholder roundtables• Workshop in Index Countries• Consultation with an Expert Review
Committee
The Index aims to adds value to each stakeholder group
The Industry • The Index sets a strategic direction for their access to medicine programmes
Examples of benefits of the Index
Our objective
Increase of access to medicine
programmes of the
pharmaceutical industry
10
• We help them to get the issue on the table
• More ESG consciousness and good management are important criteria
• Use of the Index as objective data source in negotiations with pharmaceutical companies
NGOs
Government
Investors
The data gathering process is done by the RiskMetrics Group
11
Team is headed by Afshin Mehrpouya
Company Report Cards
The first Index publication received global media coverage
13
UN Commissioner Champions IndexMary Robinson, UN High Commissioner for Human Rights from 1997 to 2002.
“I've been impressed by the ATM Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged.”
UN Guidelines
We have designed a matrix structure so that we can gradually increase the weighting of on the ground performance
18
Public Policy Influence & Advocacy
R&D
Patents &Licensing
Capacity
Equitable Pricing
Donations
Philanthropy
ATM Management
2008 Index 2009/2010 Index
Strategic Pillars Commitments Transparency Performance Innovation
Technical Areas
General Access to Medicine Strategy & Governance
Public Policy & Advocacy
Research & Development for Index Diseases
Patents & Licensing
Equitable Pricing & Registration
Technology Transfer (Capability Advancement)
Drug Donations & Philanthropic Activities
30% 30% 30% 10%The Index is an evolving tool which adapts to the
changing global healthcare
priorities.